China Embracing Microbiome Research Through Programs, Partnerships
NuBiyota is setting up a local presence to tap into China’s growing commitment to developing new therapeutics based on the microbiome, an area the country is increasingly supporting through central initiatives as part of a national precision medicine program, and where new partnerships are emerging.
You may also be interested in...
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.